BT102161

This biotech company is transforming the genomic data landscape by giving individuals full control over their DNA while enabling them to monetize their data and contribute to groundbreaking research. With over 50 pre-orders and strong interest from researchers, the platform leverages blockchain and AI to offer secure, customizable data to research institutions.

The global demand for high-quality genomic data is surging, and this company is poised to capitalize on that market while empowering individuals to actively participate in pushing scientific research forward. It’s a unique, high-growth investment opportunity in a $140B industry.

Overview

Industry: Biotechnology, Blockchain, AI-Driven Genomic Data Platform
Founded: 2018
Mission: To empower individuals to own, control, and monetize their genomic data using secure blockchain technology and AI, providing consumers with privacy and transparency while delivering high-quality, customizable data for researchers.

Problem & Solution

Problem: Current genomic platforms offer limited transparency and control for users, while researchers face challenges accessing high-quality, customizable data. Privacy and data security are major concerns, and low-quality genomic data can hinder research outcome
Solution: A blockchain-secured platform that allows individuals to fully control and monetize their DNA data. Researchers benefit from access to high-quality, customizable DNA datasets, ensuring privacy for consumers and delivering specific, accurate data insights via the company’s AI-powered data refinement platform.

Market Potential

Target Market: DNA data consumption for genetic research and consumer sequencing services.
Market Size:

→ Total Addressable Market (TAM): $40B in 2024, projected to reach $140B by 2032.
→ Serviceable Available Market (SAM): $13B focusing on consumer and research sectors.
→ Serviceable Obtainable Market (SOM): $650M through partnerships and early researcher adoption.

Product / Service

Core Product: Whole genome sequencing using advanced methodologies, stored securely on the blockchain. Consumers manage, control, and monetize their data via the platform’s web and mobile applications.
‍Technology:
• Proprietary AI platform for data refinement and variant detection.
• Blockchain-based data storage for added security and transparency.
• Advanced sequencing technologies integrated into the process for high accuracy and data quality.
Development Stage: 75% complete with upcoming beta testing slated for Q2 2025.
Intellectual Property (IP) Status: Proprietary AI and blockchain technology with strong security protocols and patentable processes.

Business Model

Revenue Streams:
• $149 per genome sequencing for consumers.
• 15% platform fee for researchers accessing data.
• 10% platform fee for genetic counselors.
• Custom research projects with scalable fees based on project requirements.
Sales Channels: Social media for direct consumer engagement, partnerships with researchers and genetic counselors, and professional outreach through industry events.

Financials

Current Financials:
• Revenue: $74,950
• Burn Rate: $1,700 per month
• Runway: Less than 60 days without new funding.
Funding Requirements: Seeking $5M to complete product development, expand marketing, and hire key personnel.
Projections:
• 1-Year: 2,000 genomes processed, generating $2.3M in net profit.
• 3-Year: 5,000 genomes processed, resulting in $8.5M in net profit.
• 5-Year: 15,000 genomes processed, with $49.7M in net profit.

Competitive Advantage

Unique Selling Proposition (USP): Consumers own and control their DNA data, while researchers access high-quality, customizable datasets via a secure, blockchain-powered platform. This offers unmatched transparency, privacy, and usability in the genomic data market.
Barriers to Entry: The combination of proprietary AI technology, blockchain integration, and industry-leading security protocols creates a significant advantage over potential competitors.

Team

Founders:

CTO: An expert in cryptography and software engineering, with decades of experience in the tech industry.
‍Key Team Members:

‍CEO: Brings extensive experience in business operations and development.
‍CBO: Leads business development efforts, focusing on driving growth and partnerships.
‍Advisors: Experts in human genetic sequencing and data security, providing strategic insight.

Competitive Analysis

Direct Competitors: None offering the same combination of blockchain-secured DNA data with AI-enhanced tools for researchers.
Indirect Competitors: Traditional DNA testing services that lack data ownership and monetization features, focusing on one-off consumer reports.

Traction

Key Metrics:

→ 50 pre-orders at $1,499 each from early adopters.
→ Survey results indicate high interest with 3,800 potential consumer signups and positive feedback from researchers.
Milestones: Blockchain ecosystem established and upgraded to a cost-efficient proof-of-stake model.

Risks & Mitigation

Operational Risks: Potential delays in scaling product delivery, mitigated through proactive customer engagement and communication.
Financial Risks: Low financial risk but closely monitoring regulatory changes in the AI, blockchain, and biotech industries.
Market Risks: Privacy concerns from consumers, addressed by blockchain’s secure and transparent framework.

Funding Requirements

Amount Sought: $5M

‍Use of Funds:
• $350K for product development
• $750K for marketing and sales
• $2.15M for capital instruments and key hires
• $900K for operational costs

Exit Strategy

Potential Exit: Acquisition by biotech, pharmaceutical, or large data companies is the most likely exit strategy. Potential buyers include major players in healthcare, tech, and data industries. An IPO is also a viable option.
Timeline: Expected exit within 3.5 years, either through acquisition or IPO, depending on market conditions and business development progress.